This test is most useful if any of these apply to you.
A 24-hour urine collection gives a pooled view of estradiol excretion during that day. The result depends on hormone production, metabolism, and elimination. It isn't a direct measure of how much estrogen your body makes or an average of your blood estradiol level.
This test can add information about urinary estrogen excretion within a broader estrogen panel. Using it to predict disease, choose hormone doses, or measure the success of a prevention plan remains exploratory. Analytical accuracy and proven clinical usefulness are separate questions.
Estradiol is the main estrogen during the reproductive years. Before menopause, the ovaries produce most circulating estradiol. Men and postmenopausal women also make it by converting testosterone and other precursor hormones in tissues such as fat. Aromatase is the enzyme responsible for this conversion.
Before estradiol leaves your body in urine, much of it is attached to chemical groups that make it easier to excrete. These attached forms are called conjugates. The urine assay releases estradiol from its conjugates before measuring it, so this result represents a different hormone fraction from routine blood estradiol.
This test uses liquid chromatography with tandem mass spectrometry, abbreviated LC-MS/MS. The method separates chemicals and identifies estradiol by its molecular properties. Results are reported in micrograms per gram of creatinine, written as mcg/g creatinine. Creatinine is a waste product generated largely by muscle. Dividing by urine creatinine helps account for urine dilution, but the reported value remains a ratio rather than an absolute amount excreted per day.
Blood and urine measurements are related, but they aren't interchangeable. A study comparing blood with first-morning urine found only moderate agreement for estradiol, with differences by sex and menopause status. That study used a different collection from this full-day test. Neither a urine concentration nor a urine estrogen ratio can be converted into a blood estradiol level.
Estrogen can stimulate the growth of breast tumors that carry estrogen receptors. Higher circulating estradiol is associated with greater breast cancer risk after menopause. Genetic studies also support a causal contribution to estrogen receptor positive breast cancer and endometrial cancer, particularly the endometrioid subtype. Those analyses estimated lifelong differences in blood estradiol; they didn't validate urinary estradiol as an individual cancer-risk test.
Studies of estrogen breakdown products have been less consistent. A pooled analysis of four cohorts using blood or urine found lower breast cancer risk with a greater proportion of certain breakdown products formed through 2-hydroxylation. This is one route the body uses to process estrogen. A later study using plasma from the Nurses' Health Study found associations that didn't match that pattern. Differences in specimens, measurements, and the proportions being compared matter.
The breakdown products in a urine panel can describe estrogen metabolism, but labeling a pathway as protective or harmful goes beyond what these studies establish. Your urine result doesn't provide a validated estimate of breast or uterine cancer risk. Family history, inherited risk variants, and established screening remain the basis of a prevention plan.
Blood studies have linked estradiol to cardiovascular outcomes, but the findings depend on who was studied and what was measured. In a cross-sectional study of 614 postmenopausal women, lower serum estradiol was associated with more calcium buildup in the abdominal aorta. Because hormone levels and artery calcification were assessed at the same time, the study couldn't establish cause and effect.
| Who Was Studied | What Was Measured | What Was Found |
|---|---|---|
| 954 young and middle-aged men without cardiovascular disease, cancer, or diabetes at enrollment | Serum estradiol measured with an antibody-based assay | Lower estradiol was associated with more cardiovascular deaths during follow-up. |
| Men in a pooled analysis of prospective cohorts | Blood estradiol measured with mass spectrometry | Very low estradiol was associated with higher all-cause mortality. |
| Men and women in the UK Biobank | A calculated free estradiol index based on serum estradiol and SHBG | A higher index was associated with lower heart failure risk in men but higher risk in premenopausal women. |
The free estradiol index is a calculation based on estradiol and its carrier protein, SHBG. It isn't a direct measurement of free estradiol. These observational findings don't establish that raising estradiol prevents heart disease or that a particular urinary result predicts survival.
In men with type 2 diabetes, a higher blood estradiol-to-testosterone ratio has also been associated with fatty liver disease. A ratio can rise because estradiol rises, testosterone falls, or both. This research hasn't established an ideal hormone ratio to pursue, and combining urinary estradiol with blood testosterone doesn't reproduce the studied measurement.
Estradiol helps limit bone breakdown. As ovarian estrogen production falls during the menopause transition, bone loss accelerates. In a study following 1,559 women, lower blood estradiol and higher FSH predicted the onset of bone loss at the spine and hip. FSH was the stronger predictor. FSH is a pituitary hormone involved in regulating ovarian function.
That study measured blood hormones. It doesn't establish a urinary estradiol threshold for bone loss or show that a falling urine result should determine when you have a bone density scan.
Estrogen signaling in the brain changes across menopause. In an imaging study of 54 women, brain estrogen receptor availability was higher after menopause, and higher availability was associated with some memory and mood measures. This was a small, cross-sectional study of receptors, not a study showing that a particular estradiol level prevents dementia. Urinary estradiol hasn't been established as a predictor of cognitive decline.
Fertility care uses blood estradiol together with ultrasound and other clinical information. The meaning of the blood result depends on the treatment stage. In a retrospective study of 1,771 fresh IVF cycles, estradiol at the trigger injection was associated with pregnancy outcomes. A separate study of 26,194 hormone-supported frozen embryo transfer cycles associated higher estradiol before progesterone treatment with lower pregnancy and live birth rates. Other research found little association between estradiol around implantation and pregnancy outcomes.
These findings concern blood measurements during specific treatment protocols. They don't establish an equivalent interpretation for a full-day urine collection. Endometriosis also involves local estrogen production and altered estrogen breakdown within lesions, which helps explain why blood or urine estradiol alone cannot diagnose or exclude it.
Evidence-backed interventions that affect your Estradiol (E2) level
Estradiol (E2) is best interpreted alongside these tests.
Estradiol (E2) is included in these pre-built panels.
An at-home 24-hour urine test that measures your estrogen levels and how your body breaks them down. Useful for understandinupg irregular cycles, fertility issues, menopause symptoms, and your hormone-related cancer risk profile.